Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 12, 2016. The document serves as a transaction notification regarding insider trading activities rather than a financial performance report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly limited to the disclosure of a specific share transaction.
Material Changes and Transaction Details
The filing discloses a transfer of Ordinary Shares (ISIN: GB0009252882) between a Person Discharging Managerial Responsibilities (PDMR) and a Person Closely Associated (PCA).
- Transaction Date: August 11, 2016
- Parties Involved: Mrs. V A Whyte (Company Secretary) and Mr. I W Whyte (Spouse/PCA).
- Nature of Transaction: Transfer of 2,941 Ordinary Shares from Mrs. Whyte to Mr. Whyte for nil consideration.
- Price: £0.00 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or strategic updates.
Investor Verification Checklist
- Verify the total shareholding of Mrs. V A Whyte and Mr. I W Whyte post-transaction.
- Confirm that the nil consideration transfer complies with internal company policies and regulatory requirements for PDMRs.
- Note that this filing contains no financial performance data; refer to the most recent Form 20-F or quarterly earnings release for financial metrics.